2023
DOI: 10.1002/clt2.12269
|View full text |Cite
|
Sign up to set email alerts
|

Comparative short‐term efficacy of endoscopic sinus surgery and biological therapies in chronic rhinosinusitis with nasal polyps: A network meta‐analysis

Jiani Chen,
Huan Wang,
Chen Zhang
et al.

Abstract: Background: To compare the safety and efficacy between endoscopic sinus surgery and different biologics in treating chronic rhinosinusitis with nasal polyps in adults by reviewing the existing clinical trials.Methods: Data extraction and risk of bias assessment were conducted by 2 independent reviewers according to the PRISMA recommendations and any disagreement was resolved by a third investigator. Outcomes were measured through a random-effects model. We searched Embase, Web of Science, MEDLINE, Cochrane, an… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
6
0

Year Published

2023
2023
2025
2025

Publication Types

Select...
6
1

Relationship

0
7

Authors

Journals

citations
Cited by 13 publications
(6 citation statements)
references
References 37 publications
0
6
0
Order By: Relevance
“…ESS showed comparable improvement in quality of life and symptoms to omalizumab, mepolizumab and benralizumab. Dupilumab seemed to be more effective than ESS in selected items in a network meta-analysis [75]. Solano J and colleagues included 38 patients in an observational study of adults on anti-IL5 m-AB treatment: 19 patients received mepolizumab, 17 benralizumab and 2 patients reslizumab.…”
Section: Comparative Studies Between Biologicsmentioning
confidence: 99%
“…ESS showed comparable improvement in quality of life and symptoms to omalizumab, mepolizumab and benralizumab. Dupilumab seemed to be more effective than ESS in selected items in a network meta-analysis [75]. Solano J and colleagues included 38 patients in an observational study of adults on anti-IL5 m-AB treatment: 19 patients received mepolizumab, 17 benralizumab and 2 patients reslizumab.…”
Section: Comparative Studies Between Biologicsmentioning
confidence: 99%
“…Since the first proof-of-concept study of dupilumab was reported in 2016, 25 clinical trials have been conducted on CRSwNP worldwide, which have demonstrated broad efficacy in CRSwNP management [99]. In the phase III SINUS 24-week and 52-week trials in adults with severe CRSwNP, dupilumab added to the standard of care significantly reduced polyp size, sinus opacification and severity of symptoms versus placebo, and was generally well tolerated [7,[100][101][102]. One clinical study conducted in the Asian population proved that long-term use of dupilumab (more than 4 years) had a satisfying effect, with significant improvement in subjective symptoms and no recurrence or significant side effects [103].…”
Section: Dupilumabmentioning
confidence: 99%
“…At our institution, ESS usually includes for each side removal of uncinate process, bilateral maxillary antrostomy to establish wide communication between the maxillary sinus and nasal cavity; antero-posterior ethmoidectomy with removal of middle turbinate; sphenoid sinus opening either trans-nasally or trans-ethmoidally and frontal sinusotomy with at least a Draf IIb procedure. [4][5][6]10 This study was approved by the local ethics committee (protocol ID 4429). All patients gave informed consent prior to inclusion.…”
Section: Study Population and Study Designmentioning
confidence: 99%
“…3 Unfortunately poor control of symptoms after surgery together with the evidence of polyps at nasal endoscopy is frequently observed, especially in severe cases. [4][5][6] Recently, some biologics have been approved for the treatment of severe uncontrolled CRSwNP and dupilumab was the first to be reimbursed in Italy. 5 The difference between 'traditional treatment' and biologics is currently a matter of discussion, and literature comparing the effectiveness of surgery to biologics is still lacking.…”
Section: Introductionmentioning
confidence: 99%
See 1 more Smart Citation